Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) Cost of Revenue: 2018-2024

Historic Cost of Revenue for Pharming Group N.V (PHAR) over the last 7 years, with Dec 2024 value amounting to $35.4 million.

  • Pharming Group N.V's Cost of Revenue rose 3.70% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.4 million, marking a year-over-year increase of 12.17%. This contributed to the annual value of $35.4 million for FY2024, which is 40.41% up from last year.
  • Per Pharming Group N.V's latest filing, its Cost of Revenue stood at $35.4 million for FY2024, which was up 40.41% from $25.2 million recorded in FY2023.
  • Pharming Group N.V's 5-year Cost of Revenue high stood at $35.4 million for FY2024, and its period low was $17.6 million during FY2022.
  • Its 3-year average for Cost of Revenue is $26.1 million, with a median of $25.2 million in 2023.
  • As far as peak fluctuations go, Pharming Group N.V's Cost of Revenue dropped by 16.93% in 2022, and later soared by 43.56% in 2023.
  • Over the past 5 years, Pharming Group N.V's Cost of Revenue (Yearly) stood at $23.5 million in 2020, then dropped by 10.18% to $21.1 million in 2021, then decreased by 16.93% to $17.6 million in 2022, then spiked by 43.56% to $25.2 million in 2023, then skyrocketed by 40.41% to $35.4 million in 2024.